![[Jcount.com]](https://www.jcount.com/wp-content/uploads/2014/08/jcount150X50.png)
![[Jcount.com]](https://www.jcount.com/wp-content/uploads/2014/08/jcountstartupslogo1.png)
What does Pronutria Biosciences do?
Pronutria Biosciences, is a clinical stage biotechnology company which is pioneering a new class of nutritional and therapeutic modalities-amino acid biologics. Amino acid biology is very important for life, to regulate biological pathways to health. Many health conditions occur when amino acid pathways are disregulated. Pronutria Bioscience provides solutions to these conditions by focusing on amino acid biology.
With insights from a clinically validated evidence, the company is pioneering new nutritional and therapeutic modalities. The approach allows them to precisely target biology which previously could not be accessed, providing a unique opportunity for addressing a variety of serious diseases and medical condition with the help of therapeutic and nutritional approaches.
How much Pronutria Biosciences was funded?
It has raised $39M in Series C funding on May 28, 2015 from Flagship Ventures and Rajiv Kaul.
Previous funding
· $10.8M in Series A funding on October 22, 2013 from Flagship Ventures
- $12.3Min Series B funding on February 14, 2014 from Enso Ventures and Flagship Ventures
What is next for Pronutria Bioventures?
The company plans to the use the fund to aggressively advance multiple programs in high unmet medical and nutritional need areas.
More about Pronutria Biosciences
Pronutria Biosciences was founded in 2010 by Noubar Afeyan, David Berry and Geoffrey von Maltzahn. It has its headquarters in Cambridge, MA. It is innovating at the frontier of amino acid biology. It has a library of more than a billion protein sequences and have developed proprietary tools for identifying disease specific product candidates. It has a team of industry leaders who are united by the commitment that live of patients and their families have to be improved. They are singularly focused on developing solutions for patients and their families facing neurodegenerative disorders, metabolic disorders and critical care conditions among other with little or no standard care at all.
